EMT is a fundamental developmental program that is hijacked in cancer. During EMT, cells lose the apical-basal polarity and cell-cell adhesion molecules, such as E-cadherin, that hold epithelial sheets together, and they instead express mesenchymal markers including N-cadherin, vimentin, and transcriptional repressors of the Snail, Slug, Twist, and Zeb families. In lung biology, this program is deeply implicated in both pathological fibrosis and carcinoma progression, since the same signaling cascades that mobilize epithelial plasticity during wound repair can be co-opted by tumor cells to detach, migrate, invade surrounding tissue, and ultimately seed metastases. Transforming growth factor beta, or TGF-β, is the most potent and widely studied inducer of EMT, activating downstream SMAD-dependent transcription as well as non-canonical pathways involving MAPK, PI3K-AKT, and Rho GTPases.

What has become increasingly clear over the past decade is that EMT is not merely a change in gene expression; it is a wholesale reorganization of cellular metabolism. Epithelial cells, which rely heavily on mitochondrial oxidative phosphorylation to generate ATP, must rewire their energetic machinery to support the demanding biosynthetic needs of a migrating, proliferating cell. Aerobic glycolysis provides rapid ATP and, critically, diverts glycolytic intermediates into branching anabolic pathways, including the pentose phosphate pathway for nucleotide synthesis and serine biosynthesis routes for lipid and amino acid generation. This metabolic flexibility is thought to be a prerequisite for successful EMT rather than simply a byproduct of it, and teasing apart cause from consequence is precisely the challenge that the new work addresses.

The research team focused on lung epithelial cells because the lung represents a clinical arena in which EMT-linked processes carry enormous weight. Idiopathic pulmonary fibrosis involves fibroblast activation and epithelial cell state transitions driven in part by TGF-β, while lung cancers, including non-small cell lung carcinoma, frequently display hybrid epithelial-mesenchymal phenotypes associated with drug resistance and metastatic spread. Understanding whether glycolytic reprogramming is a driver or a passenger in the TGF-β-induced transition of lung epithelial cells therefore has implications that extend from basic cell biology to therapeutic strategy, because metabolic enzymes are, in principle, druggable targets in a way that master transcription factors often are not.

Technically, the investigation combined TGF-β stimulation of lung epithelial cell models with measurements of glycolytic flux, lactate production, and the expression of key glycolytic enzymes such as hexokinase 2, phosphofructokinase, and lactate dehydrogenase A. These functional readouts were integrated with assessments of EMT marker expression, including the loss of E-cadherin and the gain of vimentin and N-cadherin, to establish a temporal and causal relationship between metabolic shift and phenotypic conversion. Such paired metabolic and molecular phenotyping is essential because TGF-β is known to alter numerous cellular processes simultaneously, and only carefully timed interventions can reveal which changes are required for EMT to proceed and which are secondary consequences of it.

The broader literature supports the plausibility of a causal link. Hypoxia-inducible factor 1 alpha, a master regulator of glycolytic gene expression, is stabilized not only by low oxygen but also by TGF-β signaling through mechanisms involving reactive oxygen species and mTOR pathway activation. At the same time, TGF-β suppresses the expression of PPAR gamma coactivator 1 alpha, a key driver of mitochondrial biogenesis, thereby tilting the balance away from oxidative metabolism. Glycolytic enzymes themselves have been reported to moonlight as transcriptional co-regulators; for example, certain glycolysis-associated factors can influence the activity of EMT transcription factors, creating feedback loops in which metabolism and gene expression reinforce one another. If such loops operate in lung epithelial cells, blocking glycolysis could potentially arrest or reverse the EMT program rather than merely slowing cellular energy production.

Therapeutically, the implications are considerable. Drugs that target glycolysis, ranging from hexokinase inhibitors to lactate dehydrogenase inhibitors, have been explored in preclinical cancer models for years, although clinical translation has been complicated by the dependence of normal tissues, including the brain and red blood cells, on glucose metabolism. The value of the new work lies in narrowing the therapeutic window: if glycolytic dependency is specifically induced during the EMT transition in lung epithelial cells, then transient metabolic intervention could be timed to coincide with windows of tumor plasticity, such as during the emergence of resistance to targeted therapies or immune checkpoint inhibitors, when EMT-associated states are thought to be most prominent.

The study also speaks to a conceptual shift in how the field understands cell state transitions. EMT is now recognized not as a binary switch but as a spectrum of hybrid states, with cells occupying partial epithelial-mesenchymal phenotypes that may be particularly aggressive and drug tolerant. Metabolic profiling adds an additional axis to this landscape: hybrid cells may display intermediate glycolytic dependency, fully mesenchymal cells may be the most glycolytic, and reversibility of the process may depend on whether the metabolic reprogramming has been consolidated through epigenetic modification. Stable chromatin changes at EMT gene loci could lock in a mesenchymal state even after the original TGF-β signal dissipates, suggesting that metabolic interventions would need to occur early in the transition to be effective.

For patients with lung disease, the distance between mechanistic cell biology and clinical benefit remains substantial, and the authors’ findings should be understood as foundational rather than immediately actionable. Nevertheless, the convergence of TGF-β biology, metabolic reprogramming, and epithelial plasticity in lung cells offers a coherent framework for developing biomarkers that identify patients whose tumors or fibrotic lesions are undergoing active EMT, and for designing combination regimens in which metabolic inhibitors sensitize cells to existing TGF-β pathway antagonists, kinase inhibitors, or antifibrotic agents. As the field continues to map the metabolic architecture of cell state transitions, studies like this one bring the goal of intervening in cancer progression and fibrosis at the level of cellular identity, rather than merely cellular proliferation, steadily closer to realization.

Subject of Research: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article Title: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article References: Huang, S.-W., Chen, H.-C., Peng, S.-Y., Chuang, C.-H., Chen, B.-C., Cheng, W.-H., Cools, J. M. T., Neoh, M.-M., Hsiao, S.-H., & Hsu, M.-J. (2026). The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03322-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03322-5

Keywords: aerobic glycolysis, Warburg effect, TGF-beta, epithelial-to-mesenchymal transition, lung epithelial cells, EMT, cancer metastasis, metabolic reprogramming, lactate dehydrogenase, pulmonary fibrosis, cell death discovery, glycolytic flux

Lung cancer remains a formidable adversary, with complex mechanisms of metabolic adaptation allowing malignancies to thrive even under adverse microenvironmental conditions. While mitochondrial respiration has long been recognized as a cornerstone of cellular energy production, its dysfunction in cancer cells is often regarded as a paradox, given the concurrent reliance of tumors on glycolysis—the so-called Warburg effect. However, the new research delineates a scenario in which defective respiration does not merely shift energy production pathways but critically constrains the biosynthetic capacity necessary for maintaining rapid cell division, particularly by limiting serine availability.

Serine, a nonessential amino acid, plays a pivotal role beyond its conventional function as a building block for proteins. It underpins the assembly of nucleotides, lipids, and antioxidants, fundamentally influencing cellular redox balance and one-carbon metabolism. These pathways are vital for DNA synthesis and repair, implying that serine scarcity could severely compromise tumor cell viability. The study reveals that lung cancer cells harboring mitochondrial defects exhibit a pronounced dependency on de novo serine synthesis, a metabolic route that is tightly linked to respiratory function.

The researchers employed an array of cutting-edge biochemical assays, isotope tracing experiments, and in vivo lung cancer models to dissect the metabolic fluxes within tumor cells with impaired mitochondrial electron transport chain activity. Their data explicitly demonstrate that compromised respiration diminishes the flow of carbon into serine biosynthesis pathways, precipitating a bottleneck that undermines tumor growth. Moreover, they identify that this metabolic insufficiency sensitize cells to therapeutic strategies aimed at further perturbing serine metabolism, unveiling a synthetic lethal interaction with impaired respiration.

Intriguingly, this dependency creates a metabolic vulnerability that cancer cells cannot easily circumvent. While cells generally can acquire serine from extracellular sources, the tumor microenvironment often limits nutrient availability, necessitating internal biosynthesis to meet the high anabolic demand. The study’s findings emphasize that respiratory defects exacerbate this dependency, underscoring the importance of serine synthesis as a compensatory mechanism critical for sustaining lung cancer cell proliferation under metabolic stress.

One of the landmark contributions of this research lies in unraveling how mitochondrial dysfunction influences specific metabolic pathways beyond ATP generation. By shifting focus from bioenergetics to biosynthesis, it paints a more nuanced portrait of how cancer cells negotiate metabolic constraints. The results underscore that respiratory defects impose a selective pressure on tumor metabolism, funneling resources through serine biosynthesis to fulfill proliferative and survival demands. This conceptual advance paves the way for revisiting metabolic targets in precision oncology, especially concerning lung neoplasms with inherent or acquired mitochondrial impairments.

The therapeutic implications of these insights are profound. Targeting serine biosynthetic enzymes, such as phosphoglycerate dehydrogenase (PHGDH), could disrupt the delicate metabolic balance that respiration-defective lung cancers rely upon. Combining inhibitors of serine synthesis with agents that further compromise mitochondrial function or oxidative phosphorylation might amplify anticancer efficacy by leveraging these interdependent vulnerabilities. Such combination strategies could be a game-changer in overcoming resistance mechanisms that often plague lung cancer treatment.

Furthermore, this study bridges metabolic biology with cancer genomics by associating mitochondrial respiratory mutations or dysfunctions with altered serine metabolism profiles. Characterizing patient tumors for these metabolic signatures could guide personalized therapeutic regimens, enabling clinicians to predict responsiveness to metabolism-targeted therapies. Therefore, this research contributes to the broader precision medicine paradigm, emphasizing metabolic phenotyping as a centerpiece of cancer treatment stratification.

From a mechanistic standpoint, the integration of multi-omics data in the study elucidates how impaired mitochondrial respiration reprograms cellular metabolism at a systems level. The interplay between mitochondrial electron transport chain deficits and glycolytic flux rerouting is complex, yet the focus on serine synthesis unravels a critical metabolic axis. The biochemical pathways converging on serine metabolism receive reduced precursor input due to electron transport chain inefficiency, thereby limiting the availability of one-carbon units essential for nucleotide biosynthesis and methylation reactions involved in gene expression regulation.

It is also noteworthy that the findings have broader implications beyond lung cancer. Given the centrality of mitochondria and serine metabolism in various cancers and proliferative diseases, understanding how respiration defects impose metabolic constraints could inform therapeutic strategies across oncologic disciplines. The delineation of respiration-linked serine dependency may also have ramifications in other contexts such as metabolic syndromes, neurodegenerative disorders, and aging, where mitochondrial dysfunction is a common denominator.

The study harnesses patient-derived xenograft models and genetically engineered mouse models to validate in vivo the critical role of serine synthesis in sustaining lung tumor growth under conditions of defective respiration. These preclinical models exhibit marked tumor growth retardation when serine synthesis is chemically or genetically inhibited, reinforcing the translational potential of targeting this metabolic pathway. Importantly, these findings predict that lung cancers with compromised mitochondrial function could be particularly susceptible to therapeutic interventions tailored to exploit their unique metabolic liabilities.

Moreover, the research addresses how redox homeostasis is intricately linked to serine metabolism, as serine-derived metabolites participate in glutathione synthesis, a major cellular antioxidant. Mitochondrial respiration defects can induce oxidative stress, and this study elucidates that serine synthesis pathways are critical in mitigating such stress, thereby supporting cell survival. Disruption of these pathways could therefore synergize with pro-oxidant therapies, magnifying tumor cell death and potentiating anticancer outcomes.

The metabolic plasticity observed in cancer cells, which often underpins therapeutic resistance, is challenged by the study’s observation of limited adaptive capacity in serine metabolism under respiratory impairment. This finding suggests a therapeutic window where inhibiting serine biosynthesis would be particularly effective, as tumor cells cannot compensate through alternative routes. Such vulnerabilities represent rare but exploitable chinks in the otherwise robust armor of tumor metabolic flexibility.

The authors also explore potential biomarkers reflective of mitochondrial respiration defects and altered serine metabolism that could aid in identifying patients who would most benefit from targeted metabolic therapies. The integration of metabolic imaging and molecular profiling emerges as a promising diagnostic approach to personalize treatment strategies, enabling metabolic stratification of lung cancer patients.

This comprehensive exploration of mitochondrial respiration’s functional interplay with serine biosynthesis provides a paradigm shift in understanding lung cancer metabolism. By revealing the metabolic interdependencies that sustain tumor growth, it opens prospects for innovative therapies that leverage these vulnerabilities. The research heralds a future where targeting cancer metabolism moves from conceptual promise to clinical reality, offering hope for improved management of one of the deadliest malignancies.

In conclusion, this landmark study by Cararo Lopes and colleagues exemplifies the power of integrative metabolic research in uncovering novel cancer vulnerabilities. The intricate connection between defective mitochondrial respiration and serine synthesis dependency underscores the multifaceted nature of tumor metabolism. By harnessing these insights, future therapeutic strategies can be designed to exploit metabolic bottlenecks, potentially transforming lung cancer treatment and paving the way for enhanced patient survival.

Subject of Research: Metabolic vulnerabilities in lung cancer associated with mitochondrial respiration defects and serine synthesis dependency.

Article Title: Respiration defects limit serine synthesis required for lung cancer growth and survival.

Article References:
Cararo Lopes, E., Shi, F., Sawant, A. et al. Respiration defects limit serine synthesis required for lung cancer growth and survival. Nat Commun 16, 7621 (2025). https://doi.org/10.1038/s41467-025-62911-7

Image Credits: AI Generated